{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:37:37Z","timestamp":1757623057486,"version":"3.44.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Japan Society of Transfusion Medicine"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>No established criteria exist for assessing the effectiveness of granulocyte transfusion (GTX) or biomarkers for predicting fatal infections in neutropenia. This study aimed to assess whether a novel sepsis marker, presepsin (P-SEP), is a useful prognostic indicator during GTX.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We collected frozen serum from 8 patients who had undergone GTX between September 2022 and October 2023 and measured their P-SEP levels. We compared these results with clinical records and assessed the alterations before and after GTX and their association with prognosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The post-transfusion neutrophil count increased in all cases. In 5 of 8 patients (62.5%), P-SEP levels were reduced 1 day after GTX. Pretransfusion P-SEP levels were statistically significantly lower in the group of patients who survived and overcame infection after transfusion (GTX-survived) than in the group of patients who did not survive (GTX-nonsurvived) (1493 pg\/mL vs 6658 pg\/mL, P =.04). Transfused cell counts and changes in P-SEP levels 1 day after GTX were better in the GTX-survived group than in the GTX-nonsurvived group, although the difference was not statistically significant.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>Presepsin is a biomarker that can be assessed in patients undergoing GTX for agranulocytosis. A clinically significant increase in P-SEP levels before GTX may indicate ineffective GTX and an unfavorable prognosis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/labmed\/lmae118","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T01:47:37Z","timestamp":1757382457000},"page":"469-477","source":"Crossref","is-referenced-by-count":0,"title":["Markedly elevated serum level of presepsin in agranulocytosis with hematologic malignancy: A potential prognostic factor in a single-institution retrospective study after granulocyte transfusion"],"prefix":"10.1093","volume":"56","author":[{"given":"Takuya","family":"Fukumi","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital , Okayama ,","place":["Japan"]},{"name":"Division of Transfusion and Cell therapy, Okayama University Hospital , Okayama ,","place":["Japan"]},{"name":"Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences , Okayama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital , Okayama ,","place":["Japan"]},{"name":"Division of Clinical Laboratory, Okayama University Hospital , Okayama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8021-4732","authenticated-orcid":false,"given":"Wataru","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital , Okayama ,","place":["Japan"]},{"name":"Division of Transfusion and Cell therapy, Okayama University Hospital , Okayama ,","place":["Japan"]},{"name":"Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences , Okayama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Ikeuchi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital , Okayama ,","place":["Japan"]},{"name":"Division of Transfusion and Cell therapy, Okayama University Hospital , Okayama ,","place":["Japan"]},{"name":"Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences , Okayama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Asano","sequence":"additional","affiliation":[{"name":"Division of Transfusion and Cell therapy, Okayama University Hospital , Okayama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital , Okayama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital , Okayama ,","place":["Japan"]},{"name":"Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences , Okayama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6395-7913","authenticated-orcid":false,"given":"Takumi","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital , Okayama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Seike","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital , Okayama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital , Okayama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7322-5460","authenticated-orcid":false,"given":"Noboru","family":"Asada","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital , Okayama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ennishi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital , Okayama ,","place":["Japan"]},{"name":"Center for Comprehensive Genomic Medicine, Okayama University Hospital , Okayama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital , Okayama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7014-9095","authenticated-orcid":false,"given":"Fumio","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Division of Clinical Laboratory, Okayama University Hospital , Okayama ,","place":["Japan"]},{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , Okayama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital , Okayama ,","place":["Japan"]},{"name":"Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences , Okayama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuharu","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital , Okayama ,","place":["Japan"]},{"name":"Division of Transfusion and Cell therapy, Okayama University Hospital , Okayama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"2025090821471710800_CIT0001","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nri3024","article-title":"Neutrophils in the activation and regulation of innate and adaptive immunity","volume":"11","author":"Mantovani","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"2025090821471710800_CIT0002","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1001\/archinte.1988.00380120031007","article-title":"The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation","volume":"148","author":"Talcott","year":"1988","journal-title":"Arch Intern Med"},{"key":"2025090821471710800_CIT0003","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1056\/NEJM197208242870801","article-title":"Normal granulocyte transfusion therapy: treatment of septicemia due to gram-negative bacteria","volume":"287","author":"Graw","year":"1972","journal-title":"N Engl J Med"},{"key":"2025090821471710800_CIT0004","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1056\/NEJM197703312961301","article-title":"Successful granulocyte transfusion therapy for gram-negative septicemia","volume":"296","author":"Herzig","year":"1977","journal-title":"N Engl J Med"},{"key":"2025090821471710800_CIT0005","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1182\/blood.V81.7.1883.1883","article-title":"The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis","volume":"81","author":"Bensinger","year":"1993","journal-title":"Blood"},{"key":"2025090821471710800_CIT0006","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1046\/j.1537-2995.1997.37297203521.x","article-title":"A comparative trial of granulocyte-colony-stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers","volume":"37","author":"Liles","year":"1997","journal-title":"Transfusion"},{"key":"2025090821471710800_CIT0007","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/trf.13941","article-title":"Dexamethasone promotes granulocyte mobilization by prolonging the half-life of granulocyte-colony-stimulating factor in healthy donors for granulocyte transfusions","volume":"57","author":"Hiemstra","year":"2017","journal-title":"Transfusion"},{"key":"2025090821471710800_CIT0008","first-page":"632","article-title":"Clinical efficacy and prediction of response to granulocyte transfusion therapy for patients with neutropenia-related infections","volume":"89","author":"Lee","year":"2004","journal-title":"Haematologica"},{"key":"2025090821471710800_CIT0009","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s00277-005-1055-z","article-title":"Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia","volume":"84","author":"Mousset","year":"2005","journal-title":"Ann Hematol"},{"key":"2025090821471710800_CIT0010","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000351174","article-title":"Use of healthy-donor granulocyte transfusions to treat infections in neutropenic patients with myeloid or lymphoid neoplasms: experience in 74 patients treated with 373 granulocyte transfusions","volume":"131","author":"Safdar","year":"2014","journal-title":"Acta Haematol"},{"key":"2025090821471710800_CIT0011","doi-asserted-by":"publisher","first-page":"103453","DOI":"10.1016\/j.transci.2022.103453","article-title":"Successful neutrophil engraftment supported by granulocyte transfusion in adult allogeneic transplant patients with peri-transplant active infection","volume":"61","author":"Ikegawa","year":"2022","journal-title":"Transfus Apher Sci"},{"key":"2025090821471710800_CIT0012","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1182\/blood-2015-05-645986","article-title":"Efficacy of transfusion with granulocytes from G-CSF\/dexamethasone-treated donors in neutropenic patients with infection","volume":"126","author":"Price","year":"2015","journal-title":"Blood"},{"key":"2025090821471710800_CIT0013","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.bbmt.2017.07.029","article-title":"Granulocyte transfusions: a critical reappraisal","volume":"23","author":"Valentini","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025090821471710800_CIT0014","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1086\/421997","article-title":"Serum procalcitonin and C-reactive protein levels as markers of bacterial infection a systematic review and meta-analysis","volume":"39","author":"Simon","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2025090821471710800_CIT0015","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40560-017-0246-8","article-title":"Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy","volume":"5","author":"Vijayan","year":"2017","journal-title":"J Intensive Care"},{"key":"2025090821471710800_CIT0016","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s10156-005-0400-4","article-title":"Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis","volume":"11","author":"Yaegashi","year":"2005","journal-title":"J Infect Chemother"},{"key":"2025090821471710800_CIT0017","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s10156-011-0254-x","article-title":"Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome","volume":"17","author":"Shozushima","year":"2011","journal-title":"J Infect Chemother"},{"key":"2025090821471710800_CIT0018","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4049\/jimmunol.155.1.316","article-title":"Lipopolysaccharide binding protein and CD14 modulate the synthesis of platelet-activating factor by human monocytes and mesangial and endothelial cells stimulated with lipopolysaccharide","volume":"155","author":"Camussi","year":"1995","journal-title":"J Immunol"},{"key":"2025090821471710800_CIT0019","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10156-012-0435-2","article-title":"Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study","volume":"18","author":"Endo","year":"2012","journal-title":"J Infect Chemother"},{"key":"2025090821471710800_CIT0020","doi-asserted-by":"publisher","first-page":"e22147","DOI":"10.1002\/jcla.22147","article-title":"Diagnostic performance of procalcitonin, presepsin, and C-reactive protein in patients with hematological malignancies","volume":"31","author":"Ebihara","year":"2017","journal-title":"J Clin Lab Anal"},{"key":"2025090821471710800_CIT0021","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12879-016-2116-8","article-title":"Plasma presepsin level is an early diagnostic marker of severe febrile neutropenia in hematologic malignancy patients","volume":"17","author":"Koizumi","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2025090821471710800_CIT0022","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jiac.2015.04.011","article-title":"Phagocytosis by human monocytes is required for the secretion of presepsin","volume":"21","author":"Arai","year":"2015","journal-title":"J Infect Chemother"},{"key":"2025090821471710800_CIT0023","doi-asserted-by":"publisher","first-page":"176","DOI":"10.4143\/crt.2011.43.3.176","article-title":"The usefulness of procalcitonin and C-reactive protein as early diagnostic markers of bacteremia in cancer patients with febrile neutropenia","volume":"43","author":"Kim","year":"2011","journal-title":"Cancer Res Treat"},{"key":"2025090821471710800_CIT0024","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1007\/s00520-015-2650-8","article-title":"Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis","volume":"23","author":"Wu","year":"2015","journal-title":"Support Care Cancer"},{"key":"2025090821471710800_CIT0025","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jiac.2016.04.002","article-title":"Diagnostic value of levels of presepsin (soluble CD14-subtype) in febrile neutropenia in patients with hematological disorders","volume":"22","author":"Koh","year":"2016","journal-title":"J Infect Chemother"},{"key":"2025090821471710800_CIT0026","doi-asserted-by":"publisher","first-page":"e0253842","DOI":"10.1371\/journal.pone.0253842","article-title":"The role of procalcitonin and presepsin in the septic febrile neutropenia in acute leukemia patients","volume":"16","author":"Moustafa","year":"2021","journal-title":"PLoS One"},{"key":"2025090821471710800_CIT0027","doi-asserted-by":"publisher","first-page":"e2019047","DOI":"10.4084\/MJHID.2019.047","article-title":"Comparison of presepsin, procalcitonin, interleukin-8 and C-reactive protein in predicting bacteraemia in febrile neutropenic adult patients with haematological malignancies","volume":"11","author":"Kostic","year":"2019","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2025090821471710800_CIT0028","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/labmed\/lmab002","article-title":"Usage of plasma presepsin, C-reactive protein, procalcitonin and proadrenomedullin to predict bacteremia in febril neutropenia of pediatric hematological malignancy patients","volume":"52","author":"Arikan","year":"2021","journal-title":"Lab Med"},{"key":"2025090821471710800_CIT0029","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2025090821471710800_CIT0030","doi-asserted-by":"publisher","first-page":"e94024","DOI":"10.1371\/journal.pone.0094024","article-title":"A web-based Delphi study for eliciting helpful criteria in the positive diagnosis of hemophagocytic syndrome in adult patients","volume":"9","author":"Hejblum","year":"2014","journal-title":"PLoS One"},{"key":"2025090821471710800_CIT0031","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1016\/j.cca.2011.07.024","article-title":"Development of a point-of-care assay system for measurement of presepsin (sCD14-ST)","volume":"412","author":"Okamura","year":"2011","journal-title":"Clin Chim Acta"},{"key":"2025090821471710800_CIT0032","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00134-014-3514-2","article-title":"Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial","volume":"41","author":"Masson","year":"2015","journal-title":"Intensive Care Med"},{"key":"2025090821471710800_CIT0033","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.ajem.2017.01.037","article-title":"Evaluating the value of dynamic procalcitonin and presepsin measurements for patients with severe sepsis","volume":"35","author":"Yu","year":"2017","journal-title":"Am J Emerg Med"},{"key":"2025090821471710800_CIT0034","doi-asserted-by":"publisher","first-page":"e0215791","DOI":"10.1371\/journal.pone.0215791","article-title":"Clinical evaluation of presepsin considering renal function","volume":"14","author":"Miyoshi","year":"2019","journal-title":"PLoS One"},{"key":"2025090821471710800_CIT0035","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.2169\/internalmedicine.55.6524","article-title":"Plasma levels of presepsin (soluble CD14-subtype) as a novel prognostic marker for hemophagocytic syndrome in hematological malignancies","volume":"55","author":"Nanno","year":"2016","journal-title":"Intern Med"}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/56\/5\/469\/62748075\/lmae118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/56\/5\/469\/62748075\/lmae118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T01:47:38Z","timestamp":1757382458000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/56\/5\/469\/8096346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3,26]]},"published-print":{"date-parts":[[2025,9,8]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmae118","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,3,26]]}}}